Drug guidance
Tafamidis for treating transthyretin amyloid cardiomyopathy
Condition
Cardiovascular
4 June 2024
Published on 02 Jan 2024
Last Updated on 04 Jun 2024
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Tafamidis 61 mg capsule for treating transthyretin amyloid cardiomyopathy.
Funding status
Tafamidis 61 mg capsule is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.
Tafamidis should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with transthyretin amyloid cardiomyopathy.
MAF assistance does not apply to any other formulations or strengths of tafamidis.
Tafamidis for treating transthyretin amyloid cardiomyopathy (Updated 4 Jun 24) [PDF, 141 KB]
PES Tafamidis for treating transthyretin amyloid cardiomyopathy (Updated 4 Jun 24) [PDF, 51 KB]